At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 25 enrolled
Drug / intervention
INCMGA00012 (PD-1 antibody)drug
Likely dose
INCMGA00012 (PD-1 antibody) 500 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Trial of INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic or Ampullary Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins·interventional·Posted Oct 4, 2019·Updated Jul 29, 2025
In Brief
A Phase 2 clinical trial evaluating INCMGA00012 (PD-1 antibody) for Pancreatic Cancer Non-resectable and Pancreatic Cancer Metastatic. Completed, enrolled 25 participants across 1 site.
Detailed Summary
Phase 2 study to evaluate the clinical activity of INCMGA00012 in patients with Unresectable or metastatic Adenosquamous Pancreatic or Ampullary Cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsIncyte Corporation, National Cancer Institute (NCI)
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedOct 2019
Enrollment StartApr 2020
Primary CompletionAug 2024
Study CompletionDec 2024
TodayJul 2026
First PostedOct 4, 2019
Enrollment StartApr 9, 2020
Primary CompletionAug 6, 2024
Study CompletionDec 3, 2024
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 6.7 years ago
Interventions
INCMGA00012 (PD-1 antibody)drug
INCMGA00012 (PD-1 antibody): 500 mg, 30 min IV infusion on Day 1 of each cycle (every 28 days)